Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Yes, Dr. Kelly did read most of his presentation. I'm glad that he was so well prepared. He had very little time to present a ton of information to a new audience. That's hard to do off the cuff. It wasn't an informal setup, like a ted talk where you can expound at length. He kept it on track and informative.
I agree Diesel. There will be no stopping the good news as patients walk out of the ICU's. From 2 patients to 28 to now enough for 100 patients at each hospital that participates through CSP. I expect that we'll have some big purchase orders very, very soon.
Great presentation on oncology indications. One nugget of info we didn't have previously was that CYDY is now cleared to use the 700mg dose for the cancer patients. That is extremely good news! We will likely see even better results!
The photos of the tumors with blood vessels were very interesting.
It was amazing to see how Leronlimab disrupted and destroyed their blood vessels. Without blood supply tumors will not grow and will eventually die. Outstanding.
I thought Dr. Kelly did a great job presenting. He was clear, concise and authoritative. I wish we could have heard the follow up questions but I understand that some of the information exchanged may be confidential.
Thanks for sharing the link to the presentation.
Slapped the ask with a small buy and it popped right back up. :)
Great video on Leronlimab in the Philippines. Nice to know they are seeing “astounding” improvements in the compassionate use patients. Enough doses for 100 patients can be in stock at each hospital through CSP. Dr. Nicholas stated either the distributor (Chiral) or Cytodyn can apply for an EUA and he is very hopeful one will be granted because Leronlimab is the perfect drug to treat severe and critical covid and prevent deaths.
I stand by my comment that funding was likely Streeterville. 8K confirmed that it was one of the Streeterville entities. If you go to Paulson website you can see that they’ve about 100 million in the past few years. I’m not going to do your due diligence for you. Funding is challenging for pre-revenue biotech, but you know that already.
Wow, amazing summary of the potential for Cydy. Thanks for sharing it.
Actually, he said he was not doing the trial in the US, not that they weren’t doing another trial at all. Many companies go overseas to fill trials, including Gilead for Remdesivir.
A buyout is simply not necessary. Income from one large purchase will generate enough income to get this drug rolling. A licensing/partnership deal on ONE indication will help with US FDA approval. Holding for 3 digits.
Thank you. Can't wait for the merger announcement! Glad I got in early on this one.
So Catapult is just a holding/merger shell, not the final company, right?
Per the CSP guidelines, the doctors should be reporting their results of the treated patients to the Philippine FDA in the first week of May. Stands to reason CYDY will be officially updated at that time as well.
I don't believe CYDY has sent out a PR on the new hire. The info was found by an investor and posted on Stocktwits, not announced by CYDY. I'm assuming the recently referenced investor was Streeterville, like last time. While Pourhassen referred to Paulson on the Proactive video, the context in my opinion was more about institutional investors having confidence in CYDY. Paulson already has $100 million invested in this company.
New CYDY Hire (formerly with Merck for 21+yrs): https://www.reddit.com/r/CYDY/comments/n0qbzf/22_years_at_merck_and_leaves_for_little_cytodyn/?utm_source=share&utm_medium=ios_app&utm_name=iossmf
Additional info: https://stocktwits.com/Bio4/message/322507556
HGEN's Lenzilumab excluded anyone with an O2 level below 94, so it's not a competitor to Leronlimab. Leronlimab that treats the most severe and critical patients, and will likely be used for at risk moderates too once doctors get more familiar with it.
That's great news Marksch1! Your wife's story, the lengths that you went to to get her Leronlimab, and her amazing recovery is a really wonderful and moving story. I'm so glad it's going to get picked up by the media.
Discussing this is well beyond my frame of reference, but here's something I do know. If there are autoimmune issues with any of the vaccines, Leronlimab should help treat them. MNRA vaccines may be creating yet another patient group for Leronlimab.
Something I found interesting about the Pfizer trials, is they tested participants to see if they had already had covid antibodies, and if they did have the antibodies it indicated they had previously been exposed to covid, and because of that they were not given the vaccine. However, they are not testing the general population for these antibodies now. You just show up and get a shot. Things that make you go hmmmmm.
Google Pump and Dump, I seem to recall you sold your shares right before the Vyera deal. That was unfortunate. Had you held your stock just one more day you would be deep in the green by now. I understand your frustration. Here's the thing, all is not lost. It's a great time to reinvest in Cydy as they transition from pre-revenue to revenue.
The day trading and swing trading opportunities have diminished greatly. Much more is going to be made by buying now and holding long. CYDY is the best buy in biotech right now, and maybe the best biotech investment ever. Time will tell.
There's quite a bit of research out about the new variants of concern that are multiplying at alarming rates and evading the vaccines. It appears that vaccines won't be the whole solution unfortunately. Therapeutics are going to be needed worldwide. I'm very happy that Cytodyn will be helping to save lives.
Than you Misiu143. I always appreciate the depth and breadth of knowledge that you so generously share with this group, and of course your continued advocacy for our miracle molecule.
Lerlonlimab costs less than Remdesivir, which the Philippines has been purchasing through CSP. Debunked again.
Good luck with HGEN DonDon, really I mean it. Unlike you, I don't wish for any life saving drug to fail. There is a pandemic after all and you may feel anonymous and safe there behind your computer screen, but Covid will eventually effect all of us or someone we love. The variants of concern are much more infectious than your message board rhetoric.
Actually that's incorrect DonDon. HGEN's Lenzilumab takes 3 doses to treat, so those 100,000 doses that take 12 months to make will treat 33,333 patients in 2021, not 100,000 patients. Meanwhile, Samsung can manufacture millions of doses of Leronlimab per month. Lenzilumab may prove helpful, but on a far smaller scale. Best to know what you own and manage your expectations accordingly.
In my opinion Leronlimab will render Lenzilumab irrelevant, and they won't even bother to manufacture it. That doesn't mean HGEN won't get a bunch of funding from the US government though, so at least you'll have an opportunity to time your exit strategy.
Sleep well shorts.
For anyone who doubts that there will be a global need for therapeutics: https://www.thesun.co.uk/news/14667687/scientists-world-most-mutated-covid-strain/
As far as I’m concerned they can do a trial with 2,000 patients as long as it’s a phase 4 (data and monitoring only with no placebo arm) after an EUA is granted. It would be unethical to have a placebo arm in a critical trial when the drug has such a high mortality benefit and placebo would result in near certain death.
Wrong. Leronlimab didn't kill them, the lack of it did. You have to administer a drug in order for it to work or not work. Your comment is like saying the aspirin you took last week didn't work on the headache you got today so aspirin is ineffective.
CYDY Director Naydenov exercised warrants to purchase 250,000 more shares of Cytodyn on 4/19, bringing his total to over 6 million shares. https://ir.stockpr.com/cytodyn/sec-filings-email/content/0001807094-21-000003/primary_doc.html
8K out, agreement to SELL leronlimab in Philippines.
https://ir.stockpr.com/cytodyn/sec-filings-email/content/0001193125-21-124783/d40591d8k.htm
Excellent Post Rockleo! Clear, concise and easy to understand!
Yes, karma, it's a wonderful thing. I hope everyone here gets to experience it firsthand. I don't think you can possibly assume to know what all Phd's make. Some make millions a year I'm sure, others end up working at Starbucks or posting on message boards all day for pennies. You can't generalize like that and expect to be taken even remotely seriously.
I doubt the entire company is up for sale. It's just too valuable with so many potential indications. However, I wouldn't be surprised if a licensing or partnership deal was structured for one indication, covid-19 in the U.S. for example. That would bring an infusion of cash and allow them to ramp up future trials. My preference, of course, would be Cytodyn making their own way, but I'm not so naive to believe that it wouldn't help with the FDA if one of their BP friends was involved.
If the only part remaining is receptor occupancy, why is a rolling review even necessary anymore? Once that’s filed then our BLA is complete, correct? Discuss.
Just because you are not privy to the data doesn't mean it doesn't exist. No one is under any obligation to provide it to you.
Thanks Birddogfishman! This is exactly what I was talking about. There will be no suppressing the good news coming in from overseas. Share it everywhere you can until it's heard here in the U.S.
Yes, that is exactly right. Fauci was in charge of research for new drugs for HIV/aids and he was given millions of dollars to run trials, but he latched on to AZT and ignored potential drugs (like our own Pro-140). Instead of trialing new drugs, he kept trialing AZT over and over again, refusing to acknowledge his error.
He's doing the same thing now, spearheading Remdesivir, a drug that has harmful side effects and overlooking others that will help. Can you imagine how different this pandemic would be right now, if after seeing the success of the leronlimab EIND patients in March of last year, Fauci had supported Leron through NIH, encouraging larger participation in the trials and government funding? Can you imagine how many people could have been saved in the U.S. and worldwide? Instead, he learned of the EIND results and suddenly proclaimed that monoclonal antibodies would be solution, but never once uttering Cytodyn's name. Instead of helping Cytodyn, he funneled millions of dollars to big pharma to produce their own mabs, none of which can hold a candle to Leron.
History will not be kind to Dr. Fauci.
I think it's fairly obvious that we are at a turning point with Covid. Variants are spreading everywhere, even double variants now, and people infected with more than one kind of covid at the same time! The P1 variant from Brazil is taking over in Canada and has been found in at least half of the U.S. states. The vaccines will not be effective on these variants, meanwhile the U.S. parties and protests on without a care in the world.
So far, the U.S. has pushed their vaccine program at the expense of therapeutics. They have given big pharma millions and millions of dollars, and one by one their drugs have failed. Fauci's darling Remdesivir is doing more harm than good, but still NIH keeps trialing it with everything under the sun. Remember AZT anyone?
Leronlimab is proven safe, and other countries will soon realize they have nothing to lose using it on their critical patients. It's only a matter of time before Leronlimab patients start walking out of ICU's and telling their stories. But those patients won't be Americans, they will come from countries with socialized medicine and universal health care, where big pharma doesn't control the media coverage, where every other ad on the television isn't for a big pharma drug with a list of side effects a mile long.
I don't know how many recovered patients will be necessary to usurp Remdesivir as standard of care here in the U.S. Perhaps someone should ask the eight plus FDA officials with ties to Gilead? But I'm very, very happy to be invest in this company, because Leronlimab is truly remarkable and I know it will be saving lives somewhere soon.
Yes, CYDY is going to change the face of medicine forever. It's a shame there are people out there so depraved of humanity that they would try and hold down a life saving drug, lowering themselves so far as to censor good news on this small message board. Their motives are so transparent, their tactics and employers well known. Thanks for everyone here keeping the faith despite all the slings and arrows. Your posts are appreciated.
What a beautiful letter Marksch. I hope it goes viral.
Here here, Masshysteria!!! If I could give you ten thumbs up I would. Thank you for cutting through the BS and for your clear and realistic view of exactly where we are right now. We are literally holding the solution that can change the face of the pandemic.
Is this what you're referring to about 4/21? This should make it harder to short and manipulate the stock (or at least make it more expensive to do so.) Would anyone shorting the stock be advised to cover before end of day 4/21?
Staff Statement on Fully Paid Lending
Division of Trading and Markets Staff
April 16, 2021
[1] On October 22, 2020, Commission staff issued a no-action letter regarding the broker-dealer customer protection rule, Exchange Act Rule 15c3-3, in relation to certain fully-paid lending programs operated by some broker-dealers.[2] Rule 15c3-3(b)(3) requires broker-dealers entering into agreements with their customers who lend the broker-dealers fully-paid or excess margin securities to provide the securities lenders with collateral that fully secures the loans.[3] Staff’s letter stated that the staff would not recommend enforcement action to the Commission regarding these programs for six months from issuance of the letter, or until April 22, 2021, to give firms time to come into compliance with the Rule.[4]
https://www.sec.gov/news/public-statement/staff-fully-paid-lending
Yes, it was an obvious fake email. Didn't even sound like Dr. Bream. LOL. Smells of desperation too.